Viking Therapeutics Faces Regulatory Headwinds Despite Promising Trial Results
PILLAR DIAGNOSTIC // WEEK 03
“The complexity of dual oral and subcutaneous formulation and remaining regulatory pathways is colliding with elevated takeover and growth expectations, suggesting upside is likely capped until concrete feasibility readouts arrive.”
Proposed action
Avoid initiating new long positions; consider trimming into strength or hedging exposure.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
Viking Therapeutics is advancing its dual GIP/GLP-1 receptor agonist candidate VK2735, developing both oral and subcutaneous formulations, with the subcutaneous version now entering two Phase 3 obesity trials (VANQUISH-1 and VANQUISH-2).
THE MAP
Structure & constraints
VK2735 is pursuing both oral and subcutaneous delivery routes to navigate formulation challenges and regulatory pathways for obesity therapies.
THE MOOD
Consensus & positioning
Strong GLP-1/GIP trial efficacy, safety and rapid enrollment have fueled exuberant takeover and growth narratives for VKTX, lifting investor expectations, though forecasts of a sharp EPS decline and cautious valuation viewpoints temper near-term zeal.